Dementia and neurocognitive disorders最新文献

{"title":"SoUth Korean study to PrEvent cognitive impaiRment and protect BRAIN health through Multidomain interventions via facE-to-facE and video communication plaTforms in mild cognitive impairment (SUPERBRAIN-MEET): Protocol for a Multicenter Randomized Controlled Trial.","authors":"Soo Hyun Cho, Hae Jin Kang, Yoo Kyoung Park, So Young Moon, Chang Hyung Hong, Hae Ri Na, Hong-Sun Song, Muncheong Choi, Sooin Jeong, Kyung Won Park, Hyun Sook Kim, Buong-O Chun, Jiwoo Jung, Jee Hyang Jeong, Seong Hye Choi","doi":"10.12779/dnd.2024.23.1.30","DOIUrl":"10.12779/dnd.2024.23.1.30","url":null,"abstract":"<p><strong>Background and purpose: </strong>The SoUth Korea study to PrEvent cognitive impaiRment and protect BRAIN health through lifestyle intervention (SUPERBRAIN) proved the feasibility of multidomain intervention for elderly people. One-quarter of the Korean population over 65 years of age has mild cognitive impairment (MCI). Digital health interventions may be cost-effective and have fewer spatial constraints. We aim to examine the efficacy of a multidomain intervention through both face-to-face interactions and video communication platforms using a tablet personal computer (PC) application in MCI.</p><p><strong>Methods: </strong>Three hundred participants aged 60-85 years, with MCI and at least one modifiable dementia risk factor, will be recruited from 17 centers and randomly assigned in a 1:1 ratio to the multidomain intervention and the waiting-list control groups. Participants will receive the 24-week intervention through the tablet PC SUPERBRAIN application, which encompasses the following five elements: managing metabolic and vascular risk factors, cognitive training, physical exercise, nutritional guidance, and boosting motivation. Participants will attend the interventions at a facility every 1-2 weeks. They will also engage in one or two self-administered cognitive training sessions utilizing the tablet PC application at home each week. They will participate in twice or thrice weekly online exercise sessions at home via the ZOOM platform. The primary outcome will be the change in the total scale index score of the Repeatable Battery for the Assessment of Neuropsychological Status from baseline to study end.</p><p><strong>Conclusions: </strong>This study will inform the effectiveness of a comprehensive multidomain intervention utilizing digital technologies in MCI.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT05023057.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Amyloid Positivity and Sleep Characteristics in the Elderly With Subjective Cognitive Decline.","authors":"Kyung Joon Jo, SeongHee Ho, Yun Jeong Hong, Jee Hyang Jeong, SangYun Kim, Min Jeong Wang, Seong Hye Choi, SeungHyun Han, Dong Won Yang, Kee Hyung Park","doi":"10.12779/dnd.2024.23.1.22","DOIUrl":"10.12779/dnd.2024.23.1.22","url":null,"abstract":"<p><strong>Background and purpose: </strong>Alzheimer's disease (AD) is a neurodegenerative disease characterized by a progressive decline in cognition and performance of daily activities. Recent studies have attempted to establish the relationship between AD and sleep. It is believed that patients with AD pathology show altered sleep characteristics years before clinical symptoms appear. This study evaluated the differences in sleep characteristics between cognitively asymptomatic patients with and without some amyloid burden.</p><p><strong>Methods: </strong>Sleep characteristics of 76 subjects aged 60 years or older who were diagnosed with subjective cognitive decline (SCD) but not mild cognitive impairment (MCI) or AD were measured using Fitbit^® Alta HR, a wristwatch-shaped wearable device. Amyloid deposition was evaluated using brain amyloid plaque load (BAPL) and global standardized uptake value ratio (SUVR) from fluorine-18 florbetaben positron emission tomography. Each component of measured sleep characteristics was analyzed for statistically significant differences between the amyloid-positive group and the amyloid-negative group.</p><p><strong>Results: </strong>Of the 76 subjects included in this study, 49 (64.5%) were female. The average age of the subjects was 70.72±6.09 years when the study started. 15 subjects were classified as amyloid-positive based on BAPL. The average global SUVR was 1.598±0.263 in the amyloid-positive group and 1.187±0.100 in the amyloid-negative group. Time spent in slow-wave sleep (SWS) was significantly lower in the amyloid-positive group (39.4±13.1 minutes) than in the amyloid-negative group (49.5±13.1 minutes) (p=0.009).</p><p><strong>Conclusions: </strong>This study showed that SWS is different between the elderly SCD population with and without amyloid positivity. How SWS affects AD pathology requires further research.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Anti-Aging Standard Forest Healing Program With Multiple Visits to a Forest Facility on Cognition in Older Age Patients.","authors":"Jinseok Park, Sheng-Min Wang, Dong Woo Kang, Beom Lee, Hojin Choi","doi":"10.12779/dnd.2024.23.1.44","DOIUrl":"10.12779/dnd.2024.23.1.44","url":null,"abstract":"<p><strong>Background and purpose: </strong>The anti-aging standard forest healing program (ASFHP), which uses forest therapy, was reported to be effective in improving psychological, physical, and cognitive functions. However, there are several challenges to directly visiting the forest. This study aimed to investigate the impact of multi-session ASFHP with forest visit on the mental and physical health of the older people with visits to forest facilities and compared them with those of the same program conducted indoors.</p><p><strong>Methods: </strong>Individuals aged over 70 years with concerns about cognitive decline were recruited at dementia relief centers and divided into control and experimental groups. A total of 33 people were administered ASFHP under the supervision of a forest therapy instructor. The control group stayed indoors, while the experimental group visited a forest healing center and repeated the program 20 weeks.</p><p><strong>Results: </strong>The multiple-session ASFHP positively affected cognitive impairment screening test (CIST) total scores (<i>p</i>=0.002), memory (<i>p</i>=0.014), Korean version of the Repeatable Battery for the Assessment of Neuropsychological Status total scores (<i>p</i><0.001), immediate recall (<i>p</i>=0.001), visuospatial/construction (<i>p</i><0.001), language (<i>p</i><0.001), forest healing standard questionnaire total scores (<i>p</i>=0.002), and cognitive function (<i>p</i>=0.019), regardless of location. The forest visits during the ASFHP showed positive effects on orientation (<i>p</i>=0.035), delayed recall (<i>p</i>=0.042), emotional stability (<i>p</i>=0.032), physical activity (<i>p</i>=0.005), and health (<i>p</i>=0.022). The CIST scores of the memory domain were the strongest indicator of the multiple-session ASFHP effects.</p><p><strong>Conclusions: </strong>The 20-week multi-session ASFHP with forest visit showed effects on cognitive improvement and physical and emotional stability compared to indoor education.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Usefulness of ¹⁸F-FDG PET to Differentiate Subtypes of Dementia: The Systematic Review and Meta-Analysis.","authors":"Seunghee Na, Dong Woo Kang, Geon Ha Kim, Ko Woon Kim, Yeshin Kim, Hee-Jin Kim, Kee Hyung Park, Young Ho Park, Gihwan Byeon, Jeewon Suh, Joon Hyun Shin, YongSoo Shim, YoungSoon Yang, Yoo Hyun Um, Seong-Il Oh, Sheng-Min Wang, Bora Yoon, Hai-Jeon Yoon, Sun Min Lee, Juyoun Lee, Jin San Lee, Hak Young Rhee, Jae-Sung Lim, Young Hee Jung, Juhee Chin, Yun Jeong Hong, Hyemin Jang, Hongyoon Choi, Miyoung Choi, Jae-Won Jang","doi":"10.12779/dnd.2024.23.1.54","DOIUrl":"10.12779/dnd.2024.23.1.54","url":null,"abstract":"<p><strong>Background and purpose: </strong>Dementia subtypes, including Alzheimer's dementia (AD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD), pose diagnostic challenges. This review examines the effectiveness of ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography (¹⁸F-FDG PET) in differentiating these subtypes for precise treatment and management.</p><p><strong>Methods: </strong>A systematic review following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines was conducted using databases like PubMed and Embase to identify studies on the diagnostic utility of ¹⁸F-FDG PET in dementia. The search included studies up to November 16, 2022, focusing on peer-reviewed journals and applying the gold-standard clinical diagnosis for dementia subtypes.</p><p><strong>Results: </strong>From 12,815 articles, 14 were selected for final analysis. For AD versus FTD, the sensitivity was 0.96 (95% confidence interval [CI], 0.88-0.98) and specificity was 0.84 (95% CI, 0.70-0.92). In the case of AD versus DLB, 18F-FDG PET showed a sensitivity of 0.93 (95% CI 0.88-0.98) and specificity of 0.92 (95% CI, 0.70-0.92). Lastly, when differentiating AD from non-AD dementias, the sensitivity was 0.86 (95% CI, 0.80-0.91) and the specificity was 0.88 (95% CI, 0.80-0.91). The studies mostly used case-control designs with visual and quantitative assessments.</p><p><strong>Conclusions: </strong>¹⁸F-FDG PET exhibits high sensitivity and specificity in differentiating dementia subtypes, particularly AD, FTD, and DLB. This method, while not a standalone diagnostic tool, significantly enhances diagnostic accuracy in uncertain cases, complementing clinical assessments and structural imaging.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Screening Questionnaire for Dementia With Lewy Bodies (DLB): the DLB Screening Questionnaire (DLBSQ).","authors":"Mincheol Park, Kyoungwon Baik, Young H Sohn, Byoung Seok Ye","doi":"10.12779/dnd.2024.23.1.11","DOIUrl":"10.12779/dnd.2024.23.1.11","url":null,"abstract":"<p><strong>Background and purpose: </strong>Although dementia with Lewy bodies (DLB) is the second most common cause of neurodegenerative dementia, its clinical prevalence is low. We developed a short and easy-to-complete DLB screening questionnaire (DLBSQ) to raise diagnostic sensitivity in routine clinical settings.</p><p><strong>Methods: </strong>A total of 501 participants were retrospectively enrolled, including 71 controls, 184 patients without DLB, and 246 patients with probable DLB. All patients underwent clinical evaluation, including core features of DLB, the DLBSQ, brain magnetic resonance imaging, and detailed neuropsychological assessments. The diagnostic performance of the DLBSQ for probable DLB was investigated using a receiver operating characteristic curve analysis.</p><p><strong>Results: </strong>Total DLBSQ score was associated with visuospatial and frontal/executive dysfunction and the diagnosis of probable DLB. The area under the receiver operating characteristic curve for total DLBSQ score was 0.727. Youden's method revealed an optimal cutoff value of 3. The sensitivity and specificity of the DLBSQ were 68.7% and 62.4%, respectively. Its discriminating performance improved when cognitive test profiles were additionally considered (area under the curve: 0.822, sensitivity: 80.6%, and specificity: 70.4%).</p><p><strong>Conclusions: </strong>The DLBSQ might be a useful screening tool for DLB in routine clinical practice with good sensitivity and specificity.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Multifocal Dural Arteriovenous Fistula Presumed to Present as a Progressive Cognitive Impairment.","authors":"Seunghee Na, Seung-Keun Lee, Eek-Sung Lee","doi":"10.12779/dnd.2024.23.1.67","DOIUrl":"10.12779/dnd.2024.23.1.67","url":null,"abstract":"","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Pathogenic Missense <i>NF1</i>-Variant Associated With Cognitive Impairment.","authors":"Faheem Arshad, Ashwin Prasad, Aparna Somaraj, Gautham Arunachal Udupi, Subasree Ramakrishnan, Suvarna Alladi","doi":"10.12779/dnd.2024.23.1.71","DOIUrl":"10.12779/dnd.2024.23.1.71","url":null,"abstract":"","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing the Power of Voice: A Deep Neural Network Model for Alzheimer's Disease Detection.","authors":"Chan-Young Park, Minsoo Kim, YongSoo Shim, Nayoung Ryoo, Hyunjoo Choi, Ho Tae Jeong, Gihyun Yun, Hunboc Lee, Hyungryul Kim, SangYun Kim, Young Chul Youn","doi":"10.12779/dnd.2024.23.1.1","DOIUrl":"10.12779/dnd.2024.23.1.1","url":null,"abstract":"<p><strong>Background and purpose: </strong>Voice, reflecting cerebral functions, holds potential for analyzing and understanding brain function, especially in the context of cognitive impairment (CI) and Alzheimer's disease (AD). This study used voice data to distinguish between normal cognition and CI or Alzheimer's disease dementia (ADD).</p><p><strong>Methods: </strong>This study enrolled 3 groups of subjects: 1) 52 subjects with subjective cognitive decline; 2) 110 subjects with mild CI; and 3) 59 subjects with ADD. Voice features were extracted using Mel-frequency cepstral coefficients and Chroma.</p><p><strong>Results: </strong>A deep neural network (DNN) model showed promising performance, with an accuracy of roughly 81% in 10 trials in predicting ADD, which increased to an average value of about 82.0%±1.6% when evaluated against unseen test dataset.</p><p><strong>Conclusions: </strong>Although results did not demonstrate the level of accuracy necessary for a definitive clinical tool, they provided a compelling proof-of-concept for the potential use of voice data in cognitive status assessment. DNN algorithms using voice offer a promising approach to early detection of AD. They could improve the accuracy and accessibility of diagnosis, ultimately leading to better outcomes for patients.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer's Disease: <i>Post Hoc</i> Analysis of Severe Impairment Battery Subscales.","authors":"Hyuk Sung Kwon, Seong-Ho Koh, Seong Hye Choi, Jee Hyang Jeong, Hae Ri Na, Chan Nyoung Lee, YoungSoon Yang, Ae Young Lee, Jae-Hong Lee, Kyung Won Park, Hyun Jeong Han, Byeong C Kim, Jinse Park, Jee-Young Lee, Kyu-Yong Lee, Sangjae Kim","doi":"10.12779/dnd.2023.22.3.100","DOIUrl":"10.12779/dnd.2023.22.3.100","url":null,"abstract":"<p><strong>Background and purpose: </strong>The efficacy and safety of GV1001 have been demonstrated in patients with moderate-to-severe Alzheimer's disease (AD). In this study, we aimed to further demonstrate the effectiveness of GV1001 using subscales of the Severe Impairment Battery (SIB), which is a validated measure to assess cognitive function in patients with moderate-to-severe AD.</p><p><strong>Methods: </strong>We performed a <i>post hoc</i> analysis of data from a 6 month, multicenter, phase 2, randomized, double-blind, placebo-controlled trial with GV1001 (ClinicalTrials.gov, NCT03184467). Patients were randomized to receive either GV1001 or a placebo for 24 weeks. In the current study, nine subscales of SIB-social interaction, memory, orientation, language, attention, praxis, visuospatial ability, construction, and orientation to name- were compared between the treatment (GV1001 1.12 mg) and placebo groups at weeks 12 and 24. The safety endpoints for these patients were also determined based on adverse events.</p><p><strong>Results: </strong>In addition to the considerable beneficial effect of GV1001 on the SIB total score, GV1001 1.12 mg showed the most significant effect on language function at 24 weeks compared to placebo in both the full analysis set (FAS) and per-protocol set (PPS) (<i>p</i>=0.017 and <i>p</i>=0.011, respectively). The rate of adverse events did not differ significantly between the 2 groups.</p><p><strong>Conclusions: </strong>Patients with moderate-to-severe AD receiving GV1001 had greater language benefits than those receiving placebo, as measured using the SIB language subscale.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7c/c8/dnd-22-100.PMC10400345.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9949514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dot-Like Hippocampal Hyperintensities on Diffusion-Weighted MRI in a Patient With Vomiting Caused by Benign Paroxysmal Positional Vertigo Without Amnesia.","authors":"Dae-Seop Shin,&nbsp;Eu Jene Choi","doi":"10.12779/dnd.2023.22.3.114","DOIUrl":"https://doi.org/10.12779/dnd.2023.22.3.114","url":null,"abstract":"Dot-like hippocampal hyperintensities on diffusion-weighted magnetic resonance imaging (DWI) are characteristic findings of transient global amnesia (TGA).1 These hyperintensities present as single or multiple hyperintensities in one or both hippocampi. However, some studies have reported that these lesions were present in patients without amnesia, a characteristic symptom of TGA.2-4 We report a case of dot-like hippocampal hyperintensities on DWI in a patient with benign paroxysmal positional vertigo without amnesia.","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/0c/dnd-22-114.PMC10400348.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9943344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}